Mast cell phenotype in benign and malignant tumors of the prostate

Tatiana Globa; Lilian Şaptefrţi; Raluca Amalia Ceauşu; Puşa Gaje; Anca Maria Cimpean; Marius Raica

doi:10.5114/pjp.2014.43965

eISSN: 2084-9869
ISSN: 1233-9687

Polish Journal of Pathology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2014
vol. 65

Send email

Copy url:

abstract:

Mast cell phenotype in benign and malignant tumors of the prostate

Tatiana Globa

,

Lilian Şaptefrţi

,

Raluca Amalia Ceauşu

,

Puşa Gaje

,

Anca Maria Cimpean

,

Marius Raica

Pol J Pathol 2014; 65 (2): 147-153

DOI: https://doi.org/10.5114/pjp.2014.43965

Online publish date: 2014/07/28

View full text Get citation

PlumX metrics:

The molecular phenotypic heterogeneity of mast cells (MCs) makes them attractive as potential therapeutic targets in anti-cancer adjuvant therapy. Mast cell aggregations observed in tumors suggested their involvement in tumor pathogenesis. Despite several studies using mast cell tryptase, MCs’ involvement in the progression of prostate tumors has not been demonstrated. The aim of our study was to identify and quantify the phenotypic heterogeneity of MCs in prostate lesions. Our study included 7 cases of normal prostate, 25 cases of benign epithelial hyperplasia and 64 cases of prostate carcinoma. MCs were immunohistochemically assessed using three markers: tryptase, chymase and CD117. Two immunophenotypes of MCs were identified in benign lesions: tryptase+/CD117+/chymase– and tryptase–/chymase+/CD117+, located in peritumoral areas. Intratumoral MC phenotype of malignant lesions was characterized by tryptase+/chymase+/CD117+, while in the peritumoral areas three different MCs phenotypes were identified: tryptase+/chymase+/CD117-, tryptase+/CD117+/chymase– and chymase+/CD117+/tryptase–. Our results suggest the correlation of chymase positive MCs of the peritumoral areas and CD117 positive MCs of the intratumoral areas with tumor grade.

keywords:

Mast cell phenotype in benign and malignant tumors of the prostate

Tatiana Globa , Lilian Şaptefrţi , Raluca Amalia Ceauşu , Puşa Gaje , Anca Maria Cimpean , Marius Raica

tryptase positive mast cells, chymase, CD117 (c-kit), prostate cancer, prostatic benign hyperplasia

Tatiana Globa

,

Lilian Şaptefrţi

,

Raluca Amalia Ceauşu

,

Puşa Gaje

,

Anca Maria Cimpean

,

Marius Raica